PURPOSE: Non-invasive early accurate detection of malignant breast cancer is paramount to the clinical management of the life-threatening disease. Here, we aim to test a small peptide targeted MRI contrast agent, ZD2-Gd(HP-DO3A), specific to an oncoprotein, extradomain-B fibronectin (EDB-FN), in the tumor microenvironment for MR molecular imaging of breast cancer. METHOD: EDB-FN expression in 4T1 and MDA-MB-231 cancers was analyzed with quantitative real-time PCR and western blot. Primary and metastatic triple negative breast cancer mouse models were developed using 4T1 and MDA-MB-231 cells. Contrast-enhanced MRI was carried out to evaluate the use of ZD2-Gd(HP-DO3A) in detecting 4T1 and MDA-MB-231 primary and metastatic tumors. RESULTS: EDB-FN was abundantly expressed in the extracellular matrix (ECM) of both the primary and metastatic TNBC tumors. In T1 -weighted MRI, ZD2-Gd(HP-DO3A) generated superior contrast enhancement in primary TNBC tumors than a nonspecific clinical agent Gd(HP-DO3A), during 30 min after contrast injection. ZD2-Gd(HP-DO3A) also produced a significant increase in contrast-to-noise ratio (CNR) of TNBC metastases, enabling sensitive localization and delineation of metastases that occulted in non-contrast-enhanced or Gd(HP-DO3A)-enhanced MRI. CONCLUSIONS: These findings potentiate the use of ZD2-Gd(HP-DO3A) for MR molecular imaging of malignant breast cancers to improve the healthcare of breast cancer patients. Magn Reson Med 79:3135-3143, 2018.
PURPOSE: Non-invasive early accurate detection of malignant breast cancer is paramount to the clinical management of the life-threatening disease. Here, we aim to test a small peptide targeted MRI contrast agent, ZD2-Gd(HP-DO3A), specific to an oncoprotein, extradomain-B fibronectin (EDB-FN), in the tumor microenvironment for MR molecular imaging of breast cancer. METHOD:EDB-FN expression in 4T1 and MDA-MB-231cancers was analyzed with quantitative real-time PCR and western blot. Primary and metastatic triple negative breast cancermouse models were developed using 4T1 and MDA-MB-231 cells. Contrast-enhanced MRI was carried out to evaluate the use of ZD2-Gd(HP-DO3A) in detecting 4T1 and MDA-MB-231 primary and metastatic tumors. RESULTS:EDB-FN was abundantly expressed in the extracellular matrix (ECM) of both the primary and metastatic TNBC tumors. In T1 -weighted MRI, ZD2-Gd(HP-DO3A) generated superior contrast enhancement in primary TNBC tumors than a nonspecific clinical agent Gd(HP-DO3A), during 30 min after contrast injection. ZD2-Gd(HP-DO3A) also produced a significant increase in contrast-to-noise ratio (CNR) of TNBC metastases, enabling sensitive localization and delineation of metastases that occulted in non-contrast-enhanced or Gd(HP-DO3A)-enhanced MRI. CONCLUSIONS: These findings potentiate the use of ZD2-Gd(HP-DO3A) for MR molecular imaging of malignant breast cancers to improve the healthcare of breast cancerpatients. Magn Reson Med 79:3135-3143, 2018.
Authors: Otto Metzger-Filho; Andrew Tutt; Evandro de Azambuja; Kamal S Saini; Giuseppe Viale; Sherene Loi; Ian Bradbury; Judith M Bliss; Hatem A Azim; Paul Ellis; Angelo Di Leo; José Baselga; Christos Sotiriou; Martine Piccart-Gebhart Journal: J Clin Oncol Date: 2012-03-26 Impact factor: 44.544
Authors: Richard S Finn; Judy Dering; Charles Ginther; Cindy A Wilson; Padraic Glaspy; Nishan Tchekmedyian; Dennis J Slamon Journal: Breast Cancer Res Treat Date: 2007-02-01 Impact factor: 4.872
Authors: Hedayatollah Hosseini; Milan M S Obradović; Martin Hoffmann; Kathryn L Harper; Maria Soledad Sosa; Melanie Werner-Klein; Lahiri Kanth Nanduri; Christian Werno; Carolin Ehrl; Matthias Maneck; Nina Patwary; Gundula Haunschild; Miodrag Gužvić; Christian Reimelt; Michael Grauvogl; Norbert Eichner; Florian Weber; Andreas D Hartkopf; Florin-Andrei Taran; Sara Y Brucker; Tanja Fehm; Brigitte Rack; Stefan Buchholz; Rainer Spang; Gunter Meister; Julio A Aguirre-Ghiso; Christoph A Klein Journal: Nature Date: 2016-12-14 Impact factor: 49.962
Authors: Ryan C Hall; Nadia R Ayat; Peter L Qiao; Amita M Vaidya; Dan Ma; Anita Aminoshariae; Ivan Stojanov; Zheng-Rong Lu Journal: Mol Imaging Biol Date: 2020-08-12 Impact factor: 3.488
Authors: Nadia R Ayat; Amita Vaidya; Grace A Yeung; Megan N Buford; Ryan C Hall; Peter L Qiao; Xin Yu; Zheng-Rong Lu Journal: Front Oncol Date: 2019-12-03 Impact factor: 6.244
Authors: Peter Qiao; Nadia R Ayat; Amita Vaidya; Songqi Gao; Wenyu Sun; Samuel Chou; Zheng Han; Hannah Gilmore; Jordan M Winter; Zheng-Rong Lu Journal: Front Oncol Date: 2020-10-30 Impact factor: 6.244